PINK1
If any of the terms on this page are unclear or you want to learn more about them click here!
PINK1 is one of the classic genes linked to early-onset Parkinson’s disease. Clinically, PINK1-related disease often resembles typical Parkinson’s, with bradykinesia, rigidity, and tremor, but it usually begins much earlier than the more common sporadic form. It is part of the same broader biological pathway as Parkin, which is why the two genes are often discussed together.
Normal function
PINK1 encodes a kinase (protein that adds a phosphate group to other proteins) that helps cells monitor mitochondrial health. When mitochondria are damaged, PINK1 accumulates on the outer mitochondrial membrane and helps recruit and activate a protein called Parkin, initiating a quality-control program that tags damaged mitochondria for removal through the mitophagy pathway.
Mutation and effect
Pathogenic PINK1 mutations usually cause loss of function. This weakens the cell’s ability to detect and clear damaged mitochondria, allowing dysfunctional organelles to accumulate resulting in increased stress within the cell, especially in neurons that require a lot of energy.
Key mechanisms involved
The main mechanisms involve mitochondrial dysfunction caused by defective mitophagy. Because mitochondria are central to ATP production and redox balance, PINK1 deficiency can shift cells into a state of chronic mitochondrial stress that becomes especially harmful in dopaminergic neurons. Oxidative stress and impaired metabolic resilience (body’s ability to clear out sugar and fat after you eat) are downstream of this mitochondrial sickness.
Implications for treatment
There is no approved therapy that specifically corrects PINK1 loss, so treatment still largely follows standard Parkinson’s care, especially levodopa-based symptom management. Mechanistically, though, PINK1 has made the field much more interested in strategies aimed at improving mitochondrial quality control, mitophagy, and cellular stress resistance.
Research focus
Research on PINK1 is focused on restoring mitochondrial surveillance (the process by which cells regularly check their mitochondria, the structures that produce a cell's energy, for damage) and finding ways to rescue defective mitophagy (the cleanup process that normally clears out mitochondria once they've been flagged as damaged). PINK1 is also a major model system for understanding how mitochondrial stress feeds into broader Parkinson's mechanisms, including ROS signaling (chemical alarm signals sent out by unstable, damage-causing molecules called reactive oxygen species), alpha-synuclein aggregation (the clumping together of a protein that builds up in the brains of people with Parkinson's), and selective neuronal vulnerability (the tendency for certain types of brain cells to be damaged more easily than others).
Inheritance
PINK1 is the second most common cause of the early-onset, inherited form of Parkinson's. It shows up in roughly 1-8% of early-onset cases. Since it's recessive and needs a changed copy from both parents, an affected person's kids will usually end up as unaffected carriers. However, in communities where carrying one changed copy is more common, an affected person's partner might also happen to be a carrier, which, in that case, each child would face a real 50/50 chance of being affected.
- Lange, L. M., & Klein, C. (2024). PINK1 Type of Young-Onset Parkinson Disease.
- Morris, H., & Lim, S.-Y. (2025). Monogenic Parkinson Disease Overview.
- Kumar, A., Tamjar, J., Waddell, A. D., et al. (2017). Structure of PINK1 and mechanisms of Parkinson’s disease-associated mutations.
- Narendra, D. P., Jin, S. M., Tanaka, A., et al. (2024). The role of PINK1-Parkin in mitochondrial quality control.
- Valente, E. M., Abou-Sleiman, P. M., Caputo, V., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1.